All In Biotech

Drug Trial Radar · NCT05635305

Zoliflodacin Bioequivalence and Drug-Drug Interaction Study

A Phase 1, Single-dose, Open-label, Randomized, 4-way Crossover Zoliflodacin Bioequivalence Study of the Reference Product (ZoliPa) With the Test Product (ZoliDr) in Healthy Adult Volunteers Under Fasted and Specific Fed Conditions Paired With an Investigation of the Effect of Cytochrome P450 3A4 Inhibition by Itraconazole on 3g Zoliflodacin (ZoliPa) Single-dose Pharmacokinetics

Last checked: Nov 20, 2026Latest source record: Mar 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Nov 9, 2022

Primary completion

Feb 7, 2023

Study completion Feb 7, 2023

Sponsor

Lead sponsor
Global Antibiotics Research and Development PartnershipAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Parexel; KCAS
First posted
Dec 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

this study will be a Phase 1, single-dose, two parallel cohorts, open-label, randomized study in healthy subjects with Cohort 1 as bioequivalence (BE) and food effect study and Cohort 2 as a drug-drug interaction (DDI) study.

Conditions

  • Healthy Volunteers

Interventions

  • Zoliflodacin PatheonDrug

    Zoliflodacin Patheon formulation to be compared with Zoliflodacin Dr Reddy's formulation during BE study (cohort 1). Itraconazole will be administered with Zoliflodacin Patheon formulation during DDI study (cohort 2)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: through study completion, an average of 5 months
  2. AUC(0-t)Time frame: through study completion, an average of 5 months
  3. AUC(0-∞)Time frame: through study completion, an average of 5 months
  4. clinically significant changes from baseline for vital signs: HRTime frame: through study completion, an average of 5 months
  5. clinically significant changes from baseline for vital signs: SBPTime frame: through study completion, an average of 5 months
  6. clinically significant changes from baseline for vital signs: DBPTime frame: through study completion, an average of 5 months
  7. clinically significant changes from baseline for ECG: PRTime frame: through study completion, an average of 5 months
  8. clinically significant changes from baseline for ECG: QRSTime frame: through study completion, an average of 5 months
  9. clinically significant changes from baseline for ECG: QTcFTime frame: through study completion, an average of 5 months
  10. TEAETime frame: through study completion, an average of 5 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel Early Phase Clinical Unit

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.